Selected article for: "capsid protein and different process"
Author: Shih, Shin‐Ru; Chen, Shu‐Jen; Hakimelahi, Gholam Hossein; Liu, Hsing‐Jang; Tseng, Chen‐Tso; Shia, Kak‐Shan
Title: Selective human enterovirus and rhinovirus inhibitors: An overview of capsid‐binding and protease‐inhibiting molecules
  • Cord-id: bkkkltdy
  • Document date: 2004_4_7
    • ID: bkkkltdy
    Snippet: The absence of effective vaccines for most viral infections highlights an urgent necessity for the design and development of effective antiviral drugs. Due to the advancement in virology since the late 1980s, several key events in the viral life cycle have been well delineated and a number of molecular targets have been validated, culminating in the emergence of many new antiviral drugs in recent years. Inhibitors against enteroviruses and rhinoviruses, responsible for about half of the human co
    Document: The absence of effective vaccines for most viral infections highlights an urgent necessity for the design and development of effective antiviral drugs. Due to the advancement in virology since the late 1980s, several key events in the viral life cycle have been well delineated and a number of molecular targets have been validated, culminating in the emergence of many new antiviral drugs in recent years. Inhibitors against enteroviruses and rhinoviruses, responsible for about half of the human common colds, are currently under active investigation. Agents targeted at either viral protein 1 (VP1), a relatively conserved capsid structure mediating viral adsorption/uncoating process, or 3C protease, which is highly conserved among different serotypes and essential for viral replication, are of great potential to become antipicornavirus drugs. © 2004 Wiley Periodicals, Inc. Med Res Rev, 24, No. 4, 449–474, 2004

    Search related documents:
    Co phrase search for related documents
    • abrupt onset and acute respiratory syndrome: 1, 2
    • acceptor moiety and active site: 1
    • active compound and acute disease: 1, 2
    • active compound and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • active find and acute disease: 1, 2
    • active find and acute respiratory syndrome: 1, 2, 3
    • active investigation and acute disease: 1, 2, 3, 4, 5
    • active investigation and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active site and acute disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute flaccid paralysis: 1
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity broad spectrum and acute disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activity broad spectrum and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity decrease and acute disease: 1, 2, 3, 4
    • activity decrease and acute myocarditis: 1
    • activity decrease and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23